Autologous Stem Cell Therapy in Patients With Multiple System Atrophy

A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Autologous Stem Cell Therapy in Patients With Multiple System Atrophy

This study investigates the safety and efficacy of autologous stem cell therapy in patients with Multiple System Atrophy (MSA), a rare and progressive neurodegenerative disorder characterized by autonomic failure, parkinsonism, and cerebellar ataxia. The trial will evaluate functional outcomes, motor performance, and quality of life compared to placebo/controlled group.

Inclusion Criteria:

• Multiple System Atrophy (MSA-P or MSA-C)
• Age range of 35 to 65 years

Exclusion Criteria:

• Other major neurological disorders
• Severe cardiac/renal/hepatic impairment
• Prior stem cell therapy